FWBI vs. VIRX, UNCY, BIVI, BOLT, ENLV, SPRB, BIOR, UBX, ONCT, and BCTX
Should you be buying First Wave BioPharma stock or one of its competitors? The main competitors of First Wave BioPharma include Viracta Therapeutics (VIRX), Unicycive Therapeutics (UNCY), BioVie (BIVI), Bolt Biotherapeutics (BOLT), Enlivex Therapeutics (ENLV), Spruce Biosciences (SPRB), Biora Therapeutics (BIOR), Unity Biotechnology (UBX), Oncternal Therapeutics (ONCT), and BriaCell Therapeutics (BCTX). These companies are all part of the "pharmaceutical preparations" industry.
Viracta Therapeutics (NASDAQ:VIRX) and First Wave BioPharma (NASDAQ:FWBI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation, community ranking and media sentiment.
31.4% of Viracta Therapeutics shares are held by institutional investors. Comparatively, 12.3% of First Wave BioPharma shares are held by institutional investors. 10.7% of Viracta Therapeutics shares are held by company insiders. Comparatively, 0.5% of First Wave BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Viracta Therapeutics presently has a consensus target price of $6.50, suggesting a potential upside of 1,014.92%. First Wave BioPharma has a consensus target price of $36.00, suggesting a potential upside of 1,116.22%. Given Viracta Therapeutics' higher probable upside, analysts clearly believe First Wave BioPharma is more favorable than Viracta Therapeutics.
Viracta Therapeutics received 17 more outperform votes than First Wave BioPharma when rated by MarketBeat users. Likewise, 72.97% of users gave Viracta Therapeutics an outperform vote while only 45.45% of users gave First Wave BioPharma an outperform vote.
Viracta Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, First Wave BioPharma has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500.
In the previous week, First Wave BioPharma's average media sentiment score of 0.00 equaled Viracta Therapeutics'average media sentiment score.
Viracta Therapeutics' return on equity of -102.83% beat First Wave BioPharma's return on equity.
Summary
Viracta Therapeutics beats First Wave BioPharma on 6 of the 11 factors compared between the two stocks.
Get First Wave BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for FWBI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FWBI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
First Wave BioPharma Competitors List
Related Companies and Tools
